Table 2 Neuro-ophthalmologic findings by treatment group
From: Neuro-ophthalmologic outcomes of standard versus hypo-fractionated stereotactic radiotherapy of AVPM
Neuro-ophthalmologic finding | Treatment group | p-value | |||
|---|---|---|---|---|---|
cFSRT | hSRT | ||||
n | Median (IQR) or n (%) | n | Median (IQR) or n (%) | ||
ΔLogMAR, worse eye | 35 | 0.00 (− 0.05, 0.10) | 13 | 0.05 (0.00, 0.50) | 0.092 |
Clinically relevant VA deterioration (ΔLogMAR ≥ 0.2), worse eye | 35 | 6 (17%) | 13 | 6 (46%) | 0.061 |
ΔMD, worse eye (dB) | 16 | 2.4 (− 0.2, 4.5) | 4 | 0.1 (− 4.2, 6.6) | 0.682 |
ΔLogMAR, better eye | 33 | 0.00 (− 0.02, 0.03) | 12 | 0.00 (0.00, 0.07) | 0.869 |
Clinically relevant VA deterioration (ΔLogMAR ≥ 0.2), better eye | 33 | 1 (3%) | 12 | 1 (8%) | 0.467 |
ΔMD, better eye (dB) | 21 | 0.6 (− 1.2, 1.7) | 5 | 1.5 (− 4.7, 2.4) | > 0.999 |
Optic disc abnormality (worse eye) | |||||
Pretreatment | 33 | Atrophy: 18 (55%) Edema: 7 (21%) Other: 0 (0%) | 11 | Atrophy: 3 (27%) Edema: 0 (0%) Other: 0 (0%) | 0.016 |
Final evaluation | 31 | Atrophy: 20 (65%) Edema: 0 (0%) Other: 0 (0%) | 11 | Atrophy: 3 (27%) Edema: 0 (0%) Other: 0 (0%) | 0.043 |
Any optic disc abnormality (atrophy, edema, or other abnormality) | |||||
Pretreatment | 33 | 25 (76%) | 11 | 3 (27%) | 0.009 |
CN V1 involvement | |||||
Pretreatment | 28 | 1 (4%) | 9 | 3 (33%) | 0.038 |
Final evaluation | 29 | 5 (17%) | 12 | 2 (17%) | > 0.999 |
Chronic ocular disease | 33 | 3 (9%) | 12 | 0 (0%) | 0.553 |
Radiation-induced Optic Neuropathy (RION) | |||||
During 1st year after treatment | 24 | 1 (4%) | 10 | 0 (0%) | > 0.999 |
Final evaluation | 31 | 1 (3%) | 11 | 0 (0%) | > 0.999 |
Radiation retinopathy | |||||
During 1st year after treatment | 25 | 1 (4%) | 10 | 0 (0%) | > 0.999 |
Final evaluation | 31 | 4 (13%) | 11 | 1 (9%) | > 0.999 |